{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:53:52Z","timestamp":1773237232963,"version":"3.50.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.ctrv.2006.08.006","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T07:46:33Z","timestamp":1170488793000},"page":"146-160","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Sean J.","family":"Whittaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2006.08.006_bib1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ctrv.2006.08.006_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO\u2013EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib3","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ctrv.2006.08.006_bib4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.132.11.1309","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"de Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.131.9.1003","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2006.08.006_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1067\/mjd.2001.117722","article-title":"A modified staging classification for cutaneous T-cell lymphoma","volume":"45","author":"Kashani-Sabet","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/archderm.127.10.1511","article-title":"Prognostic clinicopathologic factors in cutaneous T-cell lymphoma","volume":"127","author":"Marti","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7326\/0003-4819-93-2-223","article-title":"Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination","volume":"93","author":"Bunn","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2006.08.006_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib17","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib18","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/sj.jid.5700371","article-title":"Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma","volume":"126","author":"Tiemessen","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib19","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood.V89.9.3371","article-title":"Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides\/Sezary syndrome","volume":"89","author":"Thangavelu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2133.2002.04966.x","article-title":"Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides","volume":"147","author":"Mao","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1523-1747.ep12285617","article-title":"Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods","volume":"108","author":"Karenko","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib22","first-page":"250","article-title":"Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosomes","volume":"36","author":"Mao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.0022-202X.2004.22301.x","article-title":"Genomic aberrations and survival in cutaneous T cell lymphomas","volume":"122","author":"Fischer","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib24","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1158\/0008-5472.CAN-04-0366","article-title":"Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue","volume":"65","author":"Karenko","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1747.1999.00507.x","article-title":"Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas","volume":"112","author":"McGregor","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0002-9440(10)65028-6","article-title":"p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides","volume":"156","author":"Navas","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1523-1747.2003.12496.x","article-title":"Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides","volume":"121","author":"Scarisbrick","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.0906-6705.2004.00176.x","article-title":"Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma","volume":"13","author":"Rubben","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib30","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2005.11.353","article-title":"Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73","volume":"23","author":"van Doorn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2002-08-2434","article-title":"Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas","volume":"101","author":"Mao","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V93.1.260","article-title":"Constitutive and interleukin-7\/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells","volume":"93","author":"Qin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2006.08.006_bib34","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-04-1253","article-title":"Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis","volume":"64","author":"van Doorn","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2002-11-3574","article-title":"Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study","volume":"102","author":"Tracey","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.V97.2.523","article-title":"Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication","volume":"97","author":"Dummer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib37","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2006.08.006_bib38","doi-asserted-by":"crossref","first-page":"13383","DOI":"10.1074\/jbc.M313356200","article-title":"Identification of the Jak\/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression","volume":"279","author":"Lai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2006.08.006_bib39","first-page":"9048","article-title":"Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary syndrome","volume":"63","author":"Mitchell","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","article-title":"Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter","volume":"157","author":"Zhang","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib41","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1182\/blood.V87.8.3437.bloodjournal8783437","article-title":"The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin","volume":"87","author":"DeCoteau","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib42","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V88.5.1765.1765","article-title":"Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin\u2019s disease","volume":"88","author":"Wood","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib43","first-page":"176","article-title":"Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes","volume":"37","author":"Mao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0002-9440(10)63690-5","article-title":"AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells","volume":"163","author":"Watanabe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib45","doi-asserted-by":"crossref","first-page":"7628","DOI":"10.1158\/0008-5472.CAN-05-0925","article-title":"JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma","volume":"65","author":"Watanabe","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib47","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib48","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2340\/00015555655358","article-title":"Topical nitrogen mustard in early mycosis fungoides. A 12-year experience","volume":"65","author":"Zachariae","year":"1985","journal-title":"Acta Derm-Venereol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib51","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib54","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.128.7.931","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.136.6.748","article-title":"Narrowband TL-01 phototherapy for patch-stage mycosis fungoides","volume":"136","author":"Clark","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1067\/mjd.2001.110896","article-title":"\u201cHigh-dose\u201d UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides","volume":"44","author":"Zane","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib58","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0190-9622(84)70030-2","article-title":"Photochemotherapy for cutaneous T cell lymphoma. A follow-up study","volume":"10","author":"Honigsmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib62","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib63","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm-Venereol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib64","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides \u2013 a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2006.08.006_bib65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2006.08.006_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0167-8140(99)00050-X","article-title":"Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience","volume":"51","author":"Kirova","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archderm.118.3.150","article-title":"Treatment of mycosis fungoides: total-skin electron-beam irradiation vs. topical mechlorethamine therapy","volume":"118","author":"Hamminga","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib68","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib70","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0360-3016(94)00590-H","article-title":"Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides","volume":"32","author":"Becker","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2006.08.006_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0190-9622(96)90499-5","article-title":"Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma","volume":"35","author":"Wilson","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib72","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2006.08.006_bib73","first-page":"16","article-title":"Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis","volume":"107","author":"Rook","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib74","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib75","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2006.08.006_bib76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2006.08.006_bib77","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy","volume":"27","author":"Heald","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib78","first-page":"443","article-title":"Extracorporeal photochemotherapy for CTCL","volume":"337","author":"Heald","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib79","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0190-9622(92)70246-C","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"27","author":"Zic","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF00371732","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma \u2013 the Dusseldorf and Munich experience","volume":"287","author":"Prinz","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s001050050387","article-title":"Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow-up and clinical outcome in 31 skin diseases","volume":"47","author":"Owsianowski","year":"1996","journal-title":"Hautarzt"},{"key":"10.1016\/j.ctrv.2006.08.006_bib82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2567.1997.00325.x","article-title":"Extracorporeal photochemotherapy restores Th1\/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma","volume":"92","author":"Di Renzo","year":"1997","journal-title":"Immunology"},{"key":"10.1016\/j.ctrv.2006.08.006_bib83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.1997.tb03785.x","article-title":"Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study","volume":"137","author":"Miracco","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0781.1999.tb00077.x","article-title":"Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience","volume":"15","author":"Jiang","year":"1999","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ctrv.2006.08.006_bib85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2133.1999.02935.x","article-title":"Follicular mycosis fungoides","volume":"141","author":"Klemke","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2001.tb03716.x","article-title":"Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas","volume":"941","author":"Knobler","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib87","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.131.5.574","article-title":"High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma","volume":"131","author":"Marolleau","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib88","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood.V104.11.2642.2642","article-title":"Intermediate-dose interleukin-2 demonstrates activity in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"104","author":"Foss","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib89","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2006.08.006_bib92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.2001.tb03715.x","article-title":"The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma","volume":"941","author":"Berger","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib93","first-page":"29","article-title":"Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma","volume":"18","author":"Rook","year":"2002","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-0502(02)00011-3","article-title":"Transimmunization and the evolution of extracorporeal photochemotherapy","volume":"26","author":"Girardi","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/153303460200100109","article-title":"Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization","volume":"1","author":"Girardi","year":"2002","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2006.08.006_bib96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1473-0502(02)00014-9","article-title":"Transimmunization, a novel approach for tumor immunotherapy","volume":"26","author":"Berger","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2001.tb03705.x","article-title":"Cutaneous T cell lymphoma: the helping hand of dendritic cells","volume":"941","author":"Edelson","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2006.08.006_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.V104.11.743.743","article-title":"TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909","volume":"104","author":"Kim","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib99","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2006.08.006_bib100","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib102","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/bjc.1991.423","article-title":"Deoxycoformycin in the treatment of mature T-cell leukaemias","volume":"64","author":"Dearden","year":"1991","journal-title":"Br J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2006.08.006_bib103","first-page":"S103","article-title":"Clinical experience with 2\u2032-deoxycoformycin","volume":"38","author":"Catovsky","year":"1996","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/j.ctrv.2006.08.006_bib104","first-page":"65","article-title":"Successful combination chemotherapy including deoxycoformycin in a case of cutaneous T cell lymphoma","volume":"37","author":"Kodama","year":"1996","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.ctrv.2006.08.006_bib105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2\u2032-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib106","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib107","first-page":"58","article-title":"Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies","volume":"27","author":"Foss","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib108","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib109","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib110","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2006.08.006_bib111","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib112","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib113","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.2004.05712.x","article-title":"Treatment of advanced mycosis fungoides\/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy","volume":"150","author":"Quaglino","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib114","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib115","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib116","first-page":"1466","article-title":"Phase II evaluation of gemcitabine as a single agent for cutaneous T-cell lymphoma","volume":"102","author":"Talpur","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib117","first-page":"2371","article-title":"Front-line chemotherapy treatment with gemcitabine in 20 cutaneous T-cell lymphoma patients","volume":"102","author":"Zinzani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib118","first-page":"2491","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma","volume":"104","author":"Duvic","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib119","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood.V104.11.2486.2486","article-title":"CALGB 59901: results of a phase II study of 506U78 in CTCL and PTCL","volume":"104","author":"Czuczman","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2004.08.003","article-title":"Use of liposomal anthracyclines in Kaposi\u2019s sarcoma","volume":"31","author":"Krown","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib121","first-page":"4878","article-title":"Safety and efficacy of pegylated liposomal doxorubicin for the treatment of advanced cutaneous T-cell lymphoma","volume":"102","author":"Rupoli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib122","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.08.006_bib123","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib124","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib125","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V104.11.2644.2644","article-title":"Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL)","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib126","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/cc.3.5.824","article-title":"The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)","volume":"3","author":"Marks","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctrv.2006.08.006_bib127","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","article-title":"Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines","volume":"33","author":"Sakajiri","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib128","first-page":"2118","article-title":"Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr\/Abl+ human myeloid leukemia cells","volume":"63","author":"Yu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2006.08.006_bib129","doi-asserted-by":"crossref","first-page":"207s","DOI":"10.1200\/jco.2005.23.16_suppl.3061","article-title":"Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228","volume":"23","author":"Piekarz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib130","doi-asserted-by":"crossref","unstructured":"Duvic M, Talpur R, Ni X, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2006 [in press].","DOI":"10.1200\/jco.2005.23.16_suppl.6571"},{"key":"10.1016\/j.ctrv.2006.08.006_bib131","doi-asserted-by":"crossref","first-page":"422s","DOI":"10.1200\/jco.2006.24.18_suppl.7500","article-title":"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of a phase IIb trial","volume":"24","author":"Olsen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib132","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2000.n.009","article-title":"DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2006.08.006_bib133","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib134","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib135","first-page":"A57","article-title":"HuMax-CD4, a fully human monoclonal antibody: phase II trial in cutaneous T cell lymphoma","volume":"122","author":"Kim","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib136","doi-asserted-by":"crossref","first-page":"585s","DOI":"10.1200\/jco.2005.23.16_suppl.6601","article-title":"Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)","volume":"23","author":"Forero","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib137","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","article-title":"Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H)","volume":"72","author":"Gautschi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib139","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib141","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood.V104.11.4605.4605","article-title":"Phase II study of alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"104","author":"Zinzani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib142","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/eji.200324244","article-title":"Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope","volume":"33","author":"Tumenjargal","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib143","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib144","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.08.006_bib145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1702099","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect","volume":"25","author":"Burt","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2006.08.006_bib146","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1703872","article-title":"Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen","volume":"31","author":"Soligo","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2006.08.006_bib147","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib148","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","article-title":"Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma","volume":"138","author":"Guitart","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2006.08.006_bib149","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2006.08.006_bib150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br J Haematol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T17:16:09Z","timestamp":1707585369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573720600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S030573720600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2006.08.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}